Zentalis Pharmaceuticals (ZNTL) Short Interest Ratio & Short Volume $3.47 -0.48 (-12.15%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Zentalis Pharmaceuticals Short Interest DataZentalis Pharmaceuticals (ZNTL) has a short interest of 7.05 million shares. This marks a -7.96% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.5, indicating that it would take 3.5 days of the average trading volume of 1.57 million shares to cover all short positions.Current Short Interest7,050,000 sharesPrevious Short Interest7,660,000 sharesChange Vs. Previous Month-7.96%Dollar Volume Sold Short$19.25 millionShort Interest Ratio3.5 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares71,260,000 sharesPercentage of Shares Shorted9.89%Today's Trading Volume1,832,087 sharesAverage Trading Volume1,566,191 sharesToday's Volume Vs. Average117% Short Selling Zentalis Pharmaceuticals? Sign up to receive the latest short interest report for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartZNTL Short Interest Over TimeZNTL Days to Cover Over TimeZNTL Percentage of Float Shorted Over Time Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Zentalis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20247,050,000 shares $19.25 million -8.0%N/A3.5 $2.73 10/15/20247,660,000 shares $22.52 million -11.3%N/A4.3 $2.94 9/30/20248,640,000 shares $31.80 million -26.2%N/A4.9 $3.68 9/15/202411,700,000 shares $37.91 million -4.7%N/A6.3 $3.24 8/31/202412,280,000 shares $42.61 million +6.1%N/A8.4 $3.47 8/15/202411,570,000 shares $37.02 million +2.3%N/A8 $3.20 Get the Latest News and Ratings for ZNTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/202411,310,000 shares $44.00 million +8.5%N/A8.1 $3.89 7/15/202410,420,000 shares $41.47 million +8.3%N/A7.5 $3.98 6/30/20249,620,000 shares $39.35 million -46.1%N/A7.1 $4.09 6/15/202417,840,000 shares $157.71 million +1.9%N/A14.7 $8.84 5/31/202417,510,000 shares $208.02 million -5.5%N/A25.3 $11.88 5/15/202418,530,000 shares $221.90 million +5.9%N/A24.4 $11.98 4/30/202417,500,000 shares $193.55 million +5.2%N/A21.6 $11.06 4/15/202416,640,000 shares $220.81 million +7.2%N/A20.4 $13.27 3/31/202415,530,000 shares $244.75 million -7.2%N/A19.1 $15.76 3/15/202416,740,000 shares $239.72 million +15.0%N/A20.3 $14.32 2/29/202414,560,000 shares $217.09 million +1.6%N/A16 $14.91 2/15/202414,330,000 shares $180.70 million +4.8%N/A17.6 $12.61 1/31/202413,670,000 shares $161.99 million +4.6%N/A13.7 $11.85 1/15/202413,070,000 shares $186.38 million +2.5%N/A11.9 $14.26 12/31/202312,750,000 shares $193.16 million +10.0%N/A11.5 $15.15 12/15/202311,590,000 shares $170.03 million +4.5%N/A10.2 $14.67 11/30/202311,090,000 shares $124.76 million +4.8%N/A10.5 $11.25 11/15/202310,580,000 shares $124.00 million -5.0%N/A10.3 $11.72 10/31/202311,140,000 shares $182.25 million +4.1%N/A11.8 $16.36 10/15/202310,700,000 shares $202.66 million -5.1%N/A16.3 $18.94 9/30/202311,280,000 shares $226.28 million -0.1%N/A19.8 $20.06 9/15/202311,290,000 shares $264.30 million -5.9%N/A21.9 $23.41 8/31/202312,000,000 shares $318.72 million -3.2%N/A20.6 $26.56 8/15/202312,390,000 shares $342.46 million -7.0%N/A15.3 $27.64 7/31/202313,320,000 shares $355.78 million -2.9%N/A15.2 $26.71 7/15/202313,720,000 shares $385.81 million -5.4%N/A14.5 $28.12 6/30/202314,500,000 shares $409.05 million +9.3%N/A15 $28.21 6/15/202313,270,000 shares $368.24 million +7.9%N/A13.3 $27.75 5/31/202312,300,000 shares $320.29 million +15.8%N/A13.8 $26.04 5/15/202310,620,000 shares $297.57 million +8.0%N/A15.9 $28.02 4/30/20239,830,000 shares $216.55 million +9.1%N/A16.3 $22.03 4/15/20239,010,000 shares $164.34 million +1.2%N/A16.7 $18.24 3/31/20238,900,000 shares $153.08 million +10.2%N/A16.3 $17.20 3/15/20238,080,000 shares $147.62 million +0.9%N/A14.5 $18.27Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now 2/28/20238,010,000 shares $151.63 million +1.3%N/A15.8 $18.93 2/15/20237,910,000 shares $161.13 million +5.3%N/A15.4 $20.37 1/31/20237,510,000 shares $177.24 million -4.6%N/A13.3 $23.60 1/15/20237,870,000 shares $196.28 million +23.6%N/A14.3 $24.94 12/30/20226,370,000 shares $128.29 million +14.6%N/A11.9 $20.14 12/15/20225,560,000 shares $107.75 million -8.1%N/A10.9 $19.38 11/30/20226,050,000 shares $133.83 million +4.7%N/A10.4 $22.12 11/15/20225,780,000 shares $132.59 million -3.0%N/A9.7 $22.94 10/31/20225,960,000 shares $149.54 million +1.4%N/A9.9 $25.09 10/15/20225,880,000 shares $135.65 million -2.0%N/A9.5 $23.07 9/30/20226,000,000 shares $129.96 million -1.2%N/A9.5 $21.66 9/15/20226,070,000 shares $154.06 million +0.3%N/A9.1 $25.38 8/31/20226,050,000 shares $162.20 million +4.0%N/A9.3 $26.81 8/15/20225,820,000 shares $173.03 million -7.8%N/A8.8 $29.73 7/31/20226,310,000 shares $184.25 million -7.5%N/A8.3 $29.20 7/15/20226,820,000 shares $208.69 million -3.3%N/A8.5 $30.60 6/30/20227,050,000 shares $198.11 million +12.4%N/A7.6 $28.10 6/15/20226,270,000 shares $140.20 million +17.0%N/A7.1 $22.36 5/31/20225,360,000 shares $129.23 million +13.8%N/A6.4 $24.11 5/15/20224,710,000 shares $96.70 million +9.0%N/A6 $20.53 4/30/20224,320,000 shares $114.57 million -10.4%N/A6.9 $26.52 4/15/20224,820,000 shares $127.63 million +0.4%11.8%9.1 $26.48 3/31/20224,800,000 shares $221.47 million +19.4%11.7%10.6 $46.14 3/15/20224,020,000 shares $171.94 million +2.6%9.8%12 $42.77 2/28/20223,920,000 shares $195.57 million +7.7%9.6%12.6 $49.89 2/15/20223,640,000 shares $191.76 million +14.5%9.0%11.8 $52.68 1/31/20223,180,000 shares $181.51 million +1.0%7.8%11.1 $57.08 1/15/20223,150,000 shares $212.75 million -8.4%7.8%12.1 $67.54 12/31/20213,440,000 shares $289.17 million -2.0%8.5%14 $84.06 12/15/20213,510,000 shares $278.27 million +12.1%8.7%14.6 $79.28 11/30/20213,130,000 shares $256.82 million +6.5%7.7%12.4 $82.05 11/15/20212,940,000 shares $227.26 million +2.8%7.3%12.4 $77.30 10/29/20212,860,000 shares $230.06 million +5.2%7.1%11.8 $80.44 10/15/20212,720,000 shares $203.73 million +9.2%6.8%11.3 $74.90 9/30/20212,490,000 shares $165.93 million +7.8%6.2%10 $66.64 9/15/20212,310,000 shares $169.79 million +2.7%5.8%7.9 $73.50 8/31/20212,250,000 shares $153.43 million -3.4%5.6%8.2 $68.19 8/13/20212,330,000 shares $122.56 million -1.3%5.8%8.5 $52.60 7/30/20212,360,000 shares $125.58 million +3.5%6.1%8 $53.21 7/15/20212,280,000 shares $107.75 million -3.0%5.9%7.1 $47.26 6/30/20212,350,000 shares $125.02 million -2.1%6.0%6.8 $53.20 6/15/20212,400,000 shares $131.35 million -2.8%6.7%7.7 $54.73 5/28/20212,470,000 shares $137.95 million -2.4%6.8%7.9 $55.85 5/14/20212,530,000 shares $145.70 million +13.5%7.0%8.1 $57.59 4/30/20212,230,000 shares $133.67 million -29.7%6.2%7.3 $59.94 4/15/20213,170,000 shares $149.02 million -5.1%8.9%10.9 $47.01 3/31/20213,340,000 shares $134.64 million +22.3%9.4%12.2 $40.31 3/15/20212,730,000 shares $138.82 million -1.1%7.8%8.1 $50.85 2/26/20212,760,000 shares $111.53 million +23.8%7.9%7.5 $40.41 2/12/20212,230,000 shares $86.43 million -15.2%6.4%5.9 $38.76Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now 1/29/20212,630,000 shares $101.62 million -1.5%7.5%7 $38.64 1/15/20212,670,000 shares $135.96 million No Change7.4%7 $50.92 ZNTL Short Interest - Frequently Asked Questions What is Zentalis Pharmaceuticals' current short interest? Short interest is the volume of Zentalis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 7,050,000 shares of ZNTL short. Learn More on Zentalis Pharmaceuticals' current short interest. What is a good short interest ratio for Zentalis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZNTL shares currently have a short interest ratio of 4.0. Learn More on Zentalis Pharmaceuticals's short interest ratio. Is Zentalis Pharmaceuticals' short interest increasing or decreasing? Zentalis Pharmaceuticals saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 7,050,000 shares, a decrease of 8.0% from the previous total of 7,660,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Zentalis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies compare to Zentalis Pharmaceuticals: Cryoport, Inc. (6.10%), Prelude Therapeutics Incorporated (13.85%), Ironwood Pharmaceuticals, Inc. (7.03%), Phibro Animal Health Co. (2.03%), Immatics (5.60%), Collegium Pharmaceutical, Inc. (19.87%), CARGO Therapeutics, Inc. (17.43%), Prothena Co. plc (13.99%), Cullinan Therapeutics, Inc. (23.03%), 89bio, Inc. (5.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Zentalis Pharmaceuticals stock? Short selling ZNTL is an investing strategy that aims to generate trading profit from Zentalis Pharmaceuticals as its price is falling. ZNTL shares are trading down $0.48 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Zentalis Pharmaceuticals? A short squeeze for Zentalis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZNTL, which in turn drives the price of the stock up even further. How often is Zentalis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZNTL, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Cryoport Short Interest Data Prelude Therapeutics Short Interest Data Ironwood Pharmaceuticals Short Interest Data Phibro Animal Health Short Interest Data Immatics Short Interest Data Collegium Pharmaceutical Short Interest Data CARGO Therapeutics Short Interest Data Prothena Short Interest Data Cullinan Therapeutics Short Interest Data 89bio Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ZNTL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts